Efficacy and Safety of BI 1356 BS in Combination With Metformin in Patients With type2 Diabetes

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: BI 1356 BS (Drug); Glimepiride (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Boehringer Ingelheim Pharmaceuticals

Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: B.I. Pharma GmbH & Co. KG

The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as add-on therapy to metformin for comparison. The influence of several factors (gender, age, weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in this study.

Official title: A Randomised, Double-Blind, Placebo-Controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as Add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin t

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The primary endpoint in this study is the change of HbA1c from baseline to week 12.

Secondary outcome: The secondary endpoints are the change of fasting plasma glucose after 12 weeks of treatment compared to baseline and the occurrence of an absolute efficacy response, that is an HbA1c under treatment of <= 7.0%

Detailed description: This randomised, double-blind, and placebo-controlled, five parallel groups study compares 3 doses of BI 1356 BS to placebo as add-on therapy to metformin. In addition, there will be an open-label treatment arm with glimepiride. Patients with type 2 diabetes who meet the entry criteria are planned for inclusion in this trial. The randomised treatment will be double-blind within the dose groups of BI 1356 BS and placebo (i. e. each patient will receive one active treatment and two placebos matching the alternative active treatment, or three placebos, respectively).

Up to 500 patients will be enrolled into the trial in 5 countries to ensure that 375 patients are randomised to trial treatment (75 to each treatment group) and complete the trial.

Study Hypothesis:

The superiority of treatment with BI 1356 BS to placebo will be tested by the comparison of HbA1c change from baseline.

Comparison(s):

Placebo Glimepiride

Minimum age: 21 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion_Criteria:

- Male and female patients with a diagnosis of type 2 diabetes mellitus and previously

treated with metformin alone or with metformin and one other oral antidiabetic drug

- HbA1c 7. 0 9. 0% at screening for patients treated with metformin and one other oral

antidiabetic drug

- HbA1c 7. 5 10. 0% at screening for patients treated with metformin alone

- HbA1c 7. 5 10. 0% at beginning of the placebo run-in phase

- Age > 21 and < 75 years

- BMI > 25 and < 40 kg/m2 (Body Mass Index)

Exclusion_Criteria:

- Clinically relevant cardiovascular disease

- Impaired hepatic function

- Renal insufficiency or impaired renal function

- Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

- Treatment with insulin within 3 months prior to screening

Boehringer Ingelheim Investigational Site, Paris cedex 13 75651, France

Boehringer Ingelheim Investigational Site, Joue les Tours 37303, France

Boehringer Ingelheim Investigational Site, Joue Les Tours 37303, France

Euraxi Pharma, Joue les Tours 37303, France

Boehringer Ingelheim Investigational Site, Mainz 55116, Germany

Boehringer Ingelheim Investigational Site, Saarbrucken 66121, Germany

Boehringer Ingelheim Investigational Site, Wurzburg 97072, Germany

Boehringer Ingelheim Investigational Site, Neuwied 56564, Germany

Boehringer Ingelheim Investigational Site, Aschaffenburg 63739, Germany

Boehringer Ingelheim Investigational Site, Dresden 01307, Germany

Boehringer Ingelheim Investigational Site, Dusseldorf 40225, Germany

Boehringer Ingelheim Investigational Site, St. Ingbert/Oberwurzbach 66386, Germany

Boehringer Ingelheim Investigational Site, Sinsheim 74889, Germany

Boehringer Ingelheim Investigational Site, Immenstadt 87509, Germany

Boehringer Ingelheim Investigational Site, Bosenheim 55545, Germany

Boehringer Ingelheim Investigational Site, Heidelberg 69120, Germany

Boehringer Ingelheim Investigational Site, Sulzbach-Rosenberg 92237, Germany

Boehringer Ingelheim Investigational Site, Wangen 88239, Germany

Boehringer Ingelheim Investigational Site, Offenbach a. M. 63065, Germany

Boehringer Ingelheim Investigational Site, Nove Mesto nad Vahom 915 01, Slovakia

Boehringer Ingelheim Investigational Site, Banska Bystrica 97 517, Slovakia

Boehringer Ingelheim Investigational Site, Bratislava 81 465, Slovakia

Boehringer Ingelheim Investigational Site, Bratislava 84 105, Slovakia

Boehringer Ingelheim Investigational Site, Uddevalla 451 50, Sweden

Boehringer Ingelheim Investigational Site, Goteborg 417 17, Sweden

Boehringer Ingelheim Investigational Site, Uppsala 751 25, Sweden

Boehringer Ingelheim Investigational Site, Kiev 03151, Ukraine

Boehringer Ingelheim Investigational Site, Dnyepropetrovsk 49044, Ukraine

Boehringer Ingelheim Investigational Site, Kiev 02091, Ukraine

Boehringer Ingelheim Investigational Site, London NW1 2PQ, United Kingdom

Royal United Hospital, Bath BA1 3NG, United Kingdom

Birmingham Heartlands Hospital, Birmingham B9 5SS, United Kingdom

Boehringer Ingelheim Investigational Site, Glasgow G69 7AD, United Kingdom

Boehringer Ingelheim Investigational Site, Gillingham ME7 5NY, United Kingdom

Boehringer Ingelheim Investigational Site, Exeter EX2 5DW, United Kingdom

Boehringer Ingelheim Investigational Site, Dundee DD1 9SY, United Kingdom

Boehringer Ingelheim Investigational Site, Guildford GU2 7XX, United Kingdom

Boehringer Ingelheim Investigational Site, Ashford TW15 3EA, United Kingdom

Boehringer Ingelheim Investigational Site, Newcastle upon Tyne NE4 6BE, United Kingdom

Boehringer Ingelheim Investigational Site, Camberley GU15 2NN, United Kingdom

Boehringer Ingelheim Investigational Site, Glasgow G3 8YJ, United Kingdom

Boehringer Ingelheim Investigational Site, Chorely PR7 7NA, United Kingdom

Boehringer Ingelheim Investigational Site, Liverpool L22 0LG, United Kingdom

Boehringer Ingelheim Investigational Site, Manchester M15 6SX, United Kingdom

Boehringer Ingelheim Investigational Site, Reading RG2 7AG, United Kingdom

Ending date: August 2007
Last updated: May 9, 2008